全文获取类型
收费全文 | 614篇 |
免费 | 75篇 |
国内免费 | 1篇 |
出版年
2022年 | 12篇 |
2021年 | 12篇 |
2019年 | 4篇 |
2018年 | 15篇 |
2017年 | 12篇 |
2016年 | 8篇 |
2015年 | 27篇 |
2014年 | 19篇 |
2013年 | 30篇 |
2012年 | 45篇 |
2011年 | 43篇 |
2010年 | 28篇 |
2009年 | 20篇 |
2008年 | 26篇 |
2007年 | 33篇 |
2006年 | 29篇 |
2005年 | 28篇 |
2004年 | 22篇 |
2003年 | 25篇 |
2002年 | 17篇 |
2001年 | 14篇 |
2000年 | 10篇 |
1999年 | 12篇 |
1998年 | 11篇 |
1997年 | 7篇 |
1996年 | 5篇 |
1995年 | 9篇 |
1994年 | 7篇 |
1993年 | 6篇 |
1992年 | 14篇 |
1991年 | 12篇 |
1990年 | 12篇 |
1989年 | 7篇 |
1988年 | 10篇 |
1987年 | 4篇 |
1986年 | 7篇 |
1985年 | 5篇 |
1984年 | 7篇 |
1983年 | 9篇 |
1982年 | 7篇 |
1981年 | 11篇 |
1980年 | 6篇 |
1977年 | 7篇 |
1974年 | 5篇 |
1973年 | 5篇 |
1969年 | 2篇 |
1968年 | 2篇 |
1967年 | 3篇 |
1966年 | 4篇 |
1965年 | 2篇 |
排序方式: 共有690条查询结果,搜索用时 15 毫秒
681.
Richa Rathore Katharine E. Caldwell Charles Schutt Caitlyn B. Brashears Bethany C. Prudner William R. Ehrhardt Cheuk Hong Leung Heather Lin Najat C. Daw Hannah C. Beird Abigail Giles Wei-Lien Wang Alexander J. Lazar John S.A. Chrisinger J. Andrew Livingston Brian A. Van Tine 《Cell reports》2021,34(4):108678
682.
683.
Ana-Maria Pantazica André van Eerde Mihaela-Olivia Dobrica Iuliana Caras Irina Ionescu Adriana Costache Catalin Tucureanu Hege Steen Catalin Lazar Inger Heldal Sissel Haugslien Adrian Onu Crina Stavaru Norica Branza-Nichita Jihong Liu Clarke 《Plant biotechnology journal》2023,21(6):1176-1190
The recent SARS-CoV-2 pandemic has taught the world a costly lesson about the devastating consequences of viral disease outbreaks but also, the remarkable impact of vaccination in limiting life and economic losses. Vaccination against human Hepatitis B Virus (HBV), a major human pathogen affecting 290 million people worldwide, remains a key action towards viral hepatitis elimination by 2030. To meet this goal, the development of improved HBV antigens is critical to overcome non-responsiveness to standard vaccines based on the yeast-produced, small (S) envelope protein. We have recently shown that combining relevant immunogenic determinants of S and large (L) HBV proteins in chimeric antigens markedly enhances the anti-HBV immune response. However, the demand for cost-efficient, high-quality antigens remains challenging. This issue could be addressed by using plants as versatile and rapidly scalable protein production platforms. Moreover, the recent generation of plants lacking β-1,2-xylosyltransferase and α-1,3-fucosyltransferase activities (FX-KO), by CRISPR/Cas9 genome editing, enables production of proteins with “humanized” N-glycosylation. In this study, we investigated the impact of plant N-glycosylation on the immunogenic properties of a chimeric HBV S/L vaccine candidate produced in wild-type and FX-KO Nicotiana benthamiana. Prevention of β-1,2-xylose and α-1,3-fucose attachment to the HBV antigen significantly increased the immune response in mice, as compared with the wild-type plant-produced counterpart. Notably, the antibodies triggered by the FX-KO-made antigen neutralized more efficiently both wild-type HBV and a clinically relevant vaccine escape mutant. Our study validates in premiere the glyco-engineered Nicotiana benthamiana as a substantially improved host for plant production of glycoprotein vaccines. 相似文献
684.
A M Dupuy-Coin P Lazar S R Kalifat M Bouteille 《Journal of ultrastructure research》1969,27(3):244-249
685.
686.
687.
688.
689.
690.
Lazar S Popovic Gorana Matovina-Brko Maja Popovic Milica Popovic Ana Cvetanovic Ivan Nikolic Biljana Kukic Dragana Petrovic 《World journal of stem cells》2021,13(6):503-520
Relapsed or refractory non-Hodgkin's lymphomas, especially diffuse large B-cell lymphoma as well as relapsed or refractory Hodgkin lymphomas are hard-to-treat diseases. Patients who do not respond to initial therapy or experience relapse are treated with salvage regimens, and if eligible for aggressive therapy, treatment is continued with high-dose chemotherapy and autologous stem cell transplantation. Current therapy options can cure substantial numbers of patients, however for some it is still an uncurable disease. Numerous new drugs and cell therapies are being investigated for the treatment of relapsed or refractory lymphomas. Different types of immunotherapy options have shown promising results, and some have already become the standard of care. Here, we review immunotherapy options for the treatment of lymphoma and discuss the results, positions, practical aspects, and future directions of different drugs and cellular therapies for the treatment of this disease. 相似文献